Home » Seattle Genetics Terminates Collaboration With Genentech for Dacetuzumab
Seattle Genetics Terminates Collaboration With Genentech for Dacetuzumab
Seattle Genetics, Inc. reported that it has been notified by
Genentech, a wholly owned member of the Roche Group, that Genentech has elected to terminate the companies’ collaboration agreement for dacetuzumab
(SGN-40).
Earth Times
Earth Times
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May